Therapeutic Relevance of Abnormal Airway Morphology in Asthma
Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be severa
| Condition(s) | Asthma |
|---|---|
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Summary | Most individuals with asthma can effectively manage their symptoms and maintain normal lung function using inhaled medications, unfortunately, there is a subset of asthma sufferers whose symptoms, lung function, and risk of asthma attacks remain unimproved despite conventional inhaled medications. There could be several reasons for this. One possibility is that inhaled medications fail to reach the intended areas within the lungs, due to structural abnormalities within the airways themselves. Much like road conditions or closures can impede the speed and efficiency of vehicle travel, factors such as airway narrowing or mucus blockages, which are common in asthma, can obstruct the passage of inhaled medications through the airways. Our team has now optimized advanced medical imaging techniq |
| Who can participate | Inclusion Criteria: * Able and willing to provide written informed consent. * Able and willing to comply with the study protocol. * Males and females ≥ 18 years of age. * Asthma diagnosed by a respiratory physician. * Airway hyperresponsiveness (defined as methacholine PC20 ≤8mg/mL) and/or bronchodilator reversibility (defined as post-bronchodilator FEV1 improvement ≥200mL and 12%) in the last 6 months * ACQ ≥1.5 during the screening period. * Sputum eosinophils ≥3% and/or FeNO ≥35ppb during the screening period. Exclusion Criteria: * Current smoker, defined as someone having smoked ≥1 cigarette/day (or vape/pipe/cigar/marijuana) for ≥30 days within 12 months prior to screening. * Pregnant or breastfeeding * Non-English speaking * Oral corticosteroids in past 1-month * Biologic therapy in |
| Ages | 18 Years |
| Sex | All |
| Lead sponsor | McMaster University |
| Locations | Hamilton, Ontario, Canada; London, Ontario, Canada |
| Start date | 2025-06-02 |
| NCT ID | NCT06970080 |
| Official listing | https://clinicaltrials.gov/study/NCT06970080 |